INTRODUCTION {#s1}
============

Bladder cancer is the ninth most common malignancy worldwide, and the fourth most common malignancy in the United States \[[@R1], [@R2]\]. 70% of bladder cancers are nonmuscle invasive, whereas the remaining 30% are muscle invasive bladder cancers \[[@R3]\]. Life style and occupational exposure are the main etiological factors in bladder cancer \[[@R4]\]. However, only a small percentage of people develop bladder cancer after exposure to these environmental factors, indicating that genetic susceptibility plays an important role in bladder cancer development.

Glutathione S-transferases (GSTs) are members of a multigene family of phase II enzymes, which are involved in the detoxification of various carcinogens, and have been recognized as an important factor in bladder cancer development \[[@R5]\]. *GSTM1* and *GSTT1* genes are members of the GST family. *GSTM1* and *GSTT1* homozygous deletions are associated with reduced detoxification function, increased susceptibility to cytogenetic damage, and increased risk of cancer \[[@R6]--[@R8]\]. Previous meta-analyses have indicated an association of *GSTM1* and *GSTT1* deletion polymorphisms with increased bladder cancer risk \[[@R9]--[@R11]\]; however, the results have been inconsistent. Some overlapping studies were not excluded and several published studies were missing in their analysis \[[@R12], [@R13]\]. Here, we performed an updated meta-analysis to investigate the association between *GSTM1/GSTT1* deletion polymorphisms and bladder cancer susceptibility.

RESULTS {#s2}
=======

256 studies were identified from the database or manual search. According to the selection criteria, 193 studies were excluded, resulting in 63 studies for analysis \[[@R5], [@R12], [@R14]--[@R75]\]. (Figure [1](#F1){ref-type="fig"}) From these studies, data were available from 46 studies on GSTM1 null genotype (12751 cases and 15519 controls), 54 studies on GSTT1 null genotype (11817 cases and 14805 controls) and 11 studies on GSTM1/GSTT1 double-null genotype (1485 cases and 2230 controls). The essential information of the included studies is listed in Table [1](#T1){ref-type="table"}.
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###### Characteristics of patients in the studies included

  Study                 Year   Ethnicity     Source of controls   Study quality   GSMT1 null   GSTT1 null   GSTM1/ GSTT1 null                      
  --------------------- ------ ------------- -------------------- --------------- ------------ ------------ ------------------- --------- -------- --------
  Ceylan                2015   Caucasian     HB                   9               22/43        31/39        19/46               9/61      8/57     8/62
  Matic                 2014   Caucasian     HB                   8               80/63        56/58        36/101              32/82              
  Reszka                2014   Caucasian     PB                   9               149/95       165/200      30/212              77/288             
  Berber                2013   Caucasian     PB                   8               54/60        51/63        31/83               16/98     11/103   7/107
  Kang                  2013   Asian         PB                   8               65/45        103/117      64/46               128/92             
  Henríquez-Hernández   2012   Caucasian     HB                   8               23/67        17/64        60/30               40/41     17/73    8/73
  Schwender             2012   Caucasian     HB                   9               909/663      863/876                                             
  Lesseur               2012   Caucasian     HB                   7               378/275      508/420      106/556             143/780            
  Zhang                 2012   Caucasian     HB                   9               381/329      402/380                                             
  Ovsiannikov           2012   Caucasian     HB                   6               102/94       122/113      33/163              47/188             
  Marenne               2012   Caucasian     HB                   7               488/285      402/357                                             
  Öztürk                2011   Caucasian     PB                   9               98/78        51/46                                               
  Rouissi               2011   African       HB                   8               63/62        56/69        30/95               38/87              
  Salinas-Sánchez       2011   Caucasian     HB                   8                                         42/148              25/138             
  Moore                 2011   Caucasian     PB                   9                                         210/794             237/942            
  Goerlitz              2011   Caucasian     PB                   7                                         147/470             156/464            
  Cantor                2010   Caucasian     HB                   6                                         136/542             160/550            
  Lin                   2009   Caucasian     PB                   8               312/292      286/324                                             
  Altayli               2009   Caucasian     HB                   7               58/77        65/63        31/104              9/119              
  Grando                2009   Multiracial   PB                   8               40/60        33/67                                               
  Song                  2009   Asian         HB                   9               131/77       108/104      110/98              105/107   77/131   50/162
  Zupa                  2009   Caucasian     PB                   7               13/10        68/53                                               
  Covolo                2008   Caucasian     HB                   8               17/9         14/16        42/155              33/178             
  Golka                 2008   Caucasian     HB                   7               184/109      88/88                                               
  Shao                  2008   Asian         HB                   8               85/117       81/191                                              
  Cengiz                2007   Caucasian     HB                   9               18/33        11/42        18/99               11/42              
  Murta-Nascimento      2007   Caucasian     HB                   8               428/251      367/368                                             
  Zhao                  2007   Caucasian     HB                   9               324/298      317/316      103/520             519/115            
  Kellen                2007   Caucasian     PB                   7                                         30/164              61/319             
  McGrath               2006   Multiracial   HB                   8               109/161      483/439      35/156              148/776   18/173   78/844
  Kogevinas             2006   Caucasian     HB                   7                                         24/75               17/74              
  García-Closas         2005   Caucasian     HB                   7               716/422      571/561      230/916             248/889            
  Karagas               2005   Multiracial   PB                   9               163/115      211/140      53/301              83/458             
  Kellen                2005   Caucasian     PB                   7               312/267      597/466                                             
  Kim                   2005   Asian         HB                   8               92/61        73/80        71/82               89/64              
  Sobti                 2005   Asian         PB                   7               37/63        24/52        30/70               11/65              
  Srivastava            2005   Asian         PB                   9               43/63        140/230                                             
  Broberg               2005   Caucasian     PB                   8                                         7/54                22/132             
  Saad                  2005   Caucasian     PB                   9                                         26/46               14/67              
  Hung                  2004   Caucasian     HB                   8               132/69       112/102      43/158              33/181    28/173   19/195
  Moore                 2004   Multiracial   PB                   7               54/52        49/60        17/89               12/97     9/97     6/103
  Srivastava            2004   Asian         HB                   7               42/64        54/128       28/78               29/153    16/90    9/173
  Sanyal                2004   Caucasian     PB                   7                                         66/204              12/110             
  Chen                  2004   Asian         PB                   8                                         32/30               51/30              
  Jeong                 2003   Asian         HB                   6               75/51        99/105       68/58               113/91             
  Gago-Dominguez        2003   Multiracial   PB                   7                                         50/146              34/142             
  Giannakopoulos        2002   Caucasian     HB                   9               56/33        56/91        5/84                16/131             
  Lee                   2002   Asian         HB                   8               149/83       86/79        135/97              85/80     83/149   37/128
  Ma                    2002   Asian         PB                   9               180/137      99/83        29/32               88/94              
  Kim                   2002   Asian         PB                   8                                         91/125              228/221            
  Aktas                 2001   Caucasian     HB                   6               56/47        70/132                                              
  Törüner               2001   Caucasian     PB                   7               75/46        55/66        24/97               21/100             
  Kim                   2000   Asian         HB                   7               78/34        123/97       47/65               101/119            
  Schnakenberg          2000   Caucasian     PB                   8               93/64        129/94       28/129              48/175             
  Steinhoff             2000   Caucasian     HB                   7               80/55        57/70        20/115              17/110    12/123   4/123
  Peluso                2000   Caucasian     HB                   7                                         14/108              6/48               
  Salagovic             1999   Caucasian     PB                   9               40/36        123/125      21/55               42/206             
  Lee                   1999   Asian         HB                   6                                         93/65               66/65              
  Abdel-Rahman          1998   African       PB                   7               26/11        15/19        17/20               5/29      14/23    3/31
  Katoh                 1998   Asian         PB                   7                                         46/66               53/59              
  Salagovic             1998   Caucasian     PB                   8                                         20/47               42/206             
  Brockmoller           1996   Caucasian     HB                   6               218/156      202/171                                             
  Kempkes               1996   Caucasian     PB                   7                                         20/93               31/139             

Null/present.

Abbreviations: HB, hospital-based controls; PB, population-based controls.

GSTM1 {#s2_1}
-----

46 studies described the relationship between GSTM1 polymorphism and bladder cancer susceptibility, involving 28270 individuals. Statistical heterogeneity between trials was observed in the analysis (I^2^=52.4%, P\<0.01); thus, a random-effects model was used. The pooled meta-analysis showed that the GSTM1 null genotype was associated with increased risk of bladder cancer. The pooled summary of the OR was 1.36 (95% CI: 1.25-1.47, P\<0.01) (Figure [2](#F2){ref-type="fig"}). Subgroup analyses were performed on the different ethnicity, population-based and smoking (Table [2](#T2){ref-type="table"}). The GSTM1 null genotype was associated with the elevated risk of bladder cancer in Caucasians (OR=1.34, 95%CI=1.21-1.48) and Asians (OR=1.50, 95%CI=1.31-1.71). Stratified analyses of population-based association showed a significant association of elevated bladder cancer risk with GSTM1 deletion in hospital-based (HB) studies (OR=1. 42, 95%CI=1.30-1.56) and population-based (PB) studies (OR=1.22, 95%CI=1.07-1.40). The GSTM1 null genotype was also associated with elevated risk of bladder cancer stratified by smoking status (OR 1.37, 95%CI: 1.19-1.59 for smokers and OR 1.26, 95%CI: 1.08-1.48 for non-smokers, respectively).
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###### Subgroup analysis of GSTM1/GSTT1 polymorphism and bladder cancer risk

  Subgroup analysis   Number   GSTM1   Number                    GSTT1                Number   GSTM1/GSTT1                                                                                          
  ------------------- -------- ------- ------------------------- -------------------- -------- ------------- ------------------------- --------------------- --- ------- -------------------------- ---------------------
  Caucasian           29       57/50   1.34(1.21-1.48) P\<0.01   p\<0.01;I^2^=63.9%   38       22/19         1.23(1.08-1.40) P\<0.01   P\<0.01; I^2^=61.0%   5   13/7    1.77(1.20-2.60) P\<0.01    p=0. 76; I^2^=0%
  Asians              11       55/43   1.50(1.31-1.71) P\<0.01   p=0.77; I^2^=0%      10       19/52         0.88(0.75-1.04) P=0.14    p=0.25; I^2^=21.1%    3   32/17   2.05(1.53-2.74) P\<0.01    p=0. 46; I^2^=0%
  Africans            2        55/45   1.74(0.76-3.99) p=0.19    p=0.12; I^2^=59%     2        30/36         0.79(0.52-1.22) P=0.29    p=0.61; I^2^=0%       1   38/9    6.29(1.62-24.47) P\<0.01   \-
  multiracial         4        43/30   0.10(0.89-1.36) p=0.38    p=0.62; I^2^=0%      4        22/17         0.13(0.90-1.42) P=0.09    p=0.18; I^2^=36.3%    2   9/8     1.21(0.75-1.95) P=0.43     p=0. 57; I^2^=0%
  HB                  29       57/46   1.42(1.30-1.56) P\<0.01   p\<0.01; I^2^=52%    25       26/26         1.11(0.97-1.27) P=0.14    P\<0.01; I^2^=48.8%   8   21/11   1.73(1.45-2.23) P\<0.01    p=0. 42; I^2^=0.9%
  PB                  17       54/48   1.22(1.07-1.40) P\<0.01   p=0.05; I^2^=39.3%   29       24/22         1.15(1.00-1.33) P=0.06    P\<0.01; I^2^=62.2%   3   13/6    2.28(1.22-4.25) P=0.01     p=0. 22; I^2^=33.7%
  Smoker              17       59/51   1.37(1.19-1.59) P\<0.01   p=0.04; I^2^=42.5%   16       25/23         1.05(0.93-1.19) P=0.40    p=0.17; I^2^=42.5%    1   38/20   1.18 (0.54--2.59) P=0.68   \-
  Non-smoker          17       54/49   1.26(1.08-1.48) P\<0.01   p=0.65; I^2^=0%      16       24/23         1.07(0.88-1.29) P=0.49    p=0.33; I^2^=10.4%    1   35/26   2.66 (1.22--5.81)P=0.01    \-

null genotype percentage of bladder cancer patients/ null genotype percentage of control individuals.

GSTT1 {#s2_2}
-----

54 studies described the relationship between GSTT1 polymorphism and bladder cancer susceptibility, involving 26622 individuals. Statistical heterogeneity between trials was observed in the analysis (I^2^=56.3%, P\<0.01); thus, a random-effects model was used. The pooled meta-analysis showed that the GSTT1 null genotype was associated with elevated risk of bladder cancer. The pooled summary of the OR was 1.13 (95% CI: 1.02-1.25, P\<0.01) (Figure [3](#F3){ref-type="fig"}). Subgroup analyses were performed on the different ethnicity, population-based and smoking (Table [2](#T2){ref-type="table"}). The results suggested that the GSTT1 null genotype was associated with the elevated risk of bladder cancer in Caucasians (OR=1.23, 95%CI=1.08-1.40). However, no significant association was found in Asians, Africans, and multiracial subjects. Stratified analyses of population-based association showed a weak association of elevated bladder cancer risk with GSTT1 deletion in HB studies (OR=1.11, 95%CI=0.98-1.27) and PB studies (OR=1.15, 95%CI=1.00-1.33), but without statistical significance. There was no significant association between GSTM1 null genotype and bladder cancer risk stratified by smoking status (OR 1.05, 95%CI: 0.93-1.19 for smokers and OR 1.07, 95%CI: 0.88-1.29 for nonsmokers).
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GSTM1/ GSTT1 {#s2_3}
------------

11 studies reported the relationship between GSTM1/ GSTT1 double-null and bladder cancer susceptibility, involving 3715 individuals. Statistical heterogeneity between trials was not observed in the analysis (I^2^=4%, P=0.41), so a fixed-effects model was used. The pooled meta-analysis showed that individuals with GSTM1/ GSTT1 double-null genotype were at a higher risk to develop bladder cancer than individuals with GSTM1 or GSTT1 present. The pooled summary of the OR was 1.84 (95% CI: 1.50-2.26, P\<0.01) (Figure [4](#F4){ref-type="fig"}). Subgroup analyses were performed on the different ethnicity, population-based and smoking (Table [2](#T2){ref-type="table"}). The GSTM1/ GSTT1 double-null genotype was associated with the elevated risk of bladder cancer in Caucasians (OR=1.23, 95%CI=1.08-1.40), Asians (OR=2.05, 95%CI=1.53-2.74) and Africans (OR=6.29, 95%CI=1.62-24.47). Stratified analyses of population-based association showed association of elevated bladder cancer risk with GSTM1/ GSTT1 double-null in HB studies (OR=1.73, 95%CI=1.45-2.23) and PB studies (OR=2.28, 95%CI=1.22-4.25). Only one study reported the relationship between GSTM1/ GSTT1 double-null genotype and the risk of bladder cancer stratified by smoking status; this study showed that non-smokers with GSTM1/ GSTT1 double-null genotype had an elevated bladder cancer risk (OR=2.66, 95%CI: 1.22--5.81).
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Sensitivity analysis {#s2_4}
--------------------

Sensitivity analysis was performed to assess the stability of this meta-analysis result. The influence of the individual datasets on the summary ORs was examined by repeating the meta-analysis after sequentially omitting each study. For GSTM1 null, GSTT1 null, and GSTM1/GSTT1 double-null genotypes, the ORs were not significantly affected by omitting any individual study.

Publication bias {#s2_5}
----------------

The funnel plot for the relationship between GSTM1 null genotype and bladder cancer susceptibility is shown in Figure [5A](#F5){ref-type="fig"}. The P values for Begg\'s and Egger\'s tests were 0.44 and 0.42, respectively. The results did not reveal any evidence of publication bias in this meta-analysis.

![**A**. Funnel plot of GSTM1 gene polymorphism and bladder cancer risk. **B**. Funnel plot of GSTT1 gene polymorphism and bladder cancer risk. **C**. Funnel plot of GSTT1 gene polymorphism and bladder cancer risk (Trim and fill test). **D**. Funnel plot of GSTM1/GSTT1 double-null gene polymorphism and bladder cancer risk.](oncotarget-08-3246-g005){#F5}

The funnel plot for the relationship between GSTT1 null genotype and bladder cancer susceptibility is shown in Figure [5B](#F5){ref-type="fig"}. The P values for Begg\'s and Egger\'s tests were \<0.01 and 0.02, respectively. The results revealed that the publication bias was significant. Five studies were required to make the plot symmetrical (trim and fill method) (Figure [5C](#F5){ref-type="fig"}). Moreover, LogOR and its 95%CI altered significantly after performed trim and fill method.

The funnel plot for the relationship between GSTM1/GSTT1 double-null genotype and bladder cancer susceptibility is shown in Figure [5D](#F5){ref-type="fig"}. The P values for Begg\'s and Egger\'s tests were 0.35 and 0.20, respectively. The results did not reveal any evidence of publication bias in this meta-analysis.

DISCUSSION {#s3}
==========

Both environmental and genetic factors are important in bladder carcinogenesis; however, the exact mechanisms remain unknown. Polymorphisms in GSTs may result in deficiency in GST enzyme activity and increased cancer susceptibility. Previous studies have explored the relationship between GSTM1/GSTT1 deletion polymorphisms and cancer susceptibility. However, the results were inconclusive because of different study designs, and ethnicities and lifestyles of the enrolled subjects.

To quantify the strength of the association between GSTM1/GSTT1 polymorphisms and bladder cancer risk, we performed a meta-analysis of 63 studies. GSTM1 functions in the detoxification of benzene oxide to s-phenylmercapturic acid \[[@R76]\], and its deletion is responsible for the deficiency in key enzyme activity. Our results show that the GSTM1 null genotype is associated with increased bladder cancer risk. GSTT1 also functions in the detoxification of various carcinogens \[[@R76]\]. Our study demonstrates that GSTT1 null genotype is associated with increased bladder cancer risk. The null genotype of both GSTM1 and GSTT1 is also associated with increased risk of bladder cancer.

Regarding the different ethnicities, our results suggest that the GSTM1 null genotype is associated with the elevated risk of bladder cancer in Caucasians and Asians. A similar relationship was found between the GSTT1 null genotype and bladder cancer risk in Caucasians. In addition, our results indicate that the GSTM1/GSTT1 double-null genotype is associated with elevated risk of bladder cancer in Caucasians, Asians, and Africans. This discrepancy could be explained by different effects of the GSTM1 and GSTT1 polymorphisms on bladder cancer susceptibility in different ethnic groups. Alternatively, the sample size of Asians and Africans studies might have been small, which would result in an inadequate statistical power to identify a statistically significant effect or generate a fluctuated risk estimate \[[@R77]\]. Stratified analyses of population-based association study showed a significant association of increased bladder cancer risk with GSTM1 null and GSTM1/GSTT1 double-null in HB studies and PB studies. However, this statistical significance was not found between GSTT1 null genotype and bladder cancer risk in HB studies and PB studies. This suggests that the role of GSTT1 deletion on bladder cancer susceptibility is mainly influenced by the different control individuals. It is well known that smoking is one of the main independent risk factors for bladder cancer \[[@R78]\]. After stratification by smoking status, the GSTM1 deletion was associated with an increased bladder cancer risk in both smokers and nonsmokers. However, no statistical significance was found between GSTT1 deletion and smoking status. Non-smokers with GSTM1/GSTT1 double-null genotype had an elevated bladder cancer risk. These inconsistent data may indicate the different GSTs interactions resulting in joint action. The different study weight dictated by study size may also influence the result.

Several limitations should be noted in this meta-analysis. First, several small sample size studies were included in our analysis. However, we also included some large sample size studies. Second, significant heterogeneity between trials was observed in the analysis. This heterogeneity may derive from the differences in ethnicity, population-based or individual lifestyles. Third, we detected a publication bias when we analyzed the association between GSTT1 polymorphism and bladder cancer risk. It is probably because only published and English language papers were enrolled in this study.

In summary, our meta-analysis study indicates that GSTM1 null, GSTT1 null, and GSTM1/GSTT1 double-null genotypes are associated with increased bladder cancer risk. Further high-quality large scale epidemiological studies should be performed to verify the current conclusions.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

According to the PRISMA guidelines \[[@R79]\], we performed a systematic literature search of Pubmed, Web of Knowledge, and the Cochrane Central Search Library (on May 15, 2016). Key words used included glutathione S-transferase M1, GSTM1, glutathione S-transferase T 1, GSTT1, bladder, cancer, carcinoma, and tumor. All abstracts and review studies on this topic were reviewed. Reference lists of review studies were searched by hand.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The eligible studies had to meet the following inclusion criteria: (1) The studies had to evaluate the association between GSTM1 or GSTT1 polymorphism and bladder cancer risk; (2) The report contained key information that could yield odds ratio (OR) by the data provided; (3) Studies were published in English; and (4) Conference abstracts, reviews and unpublished reports were not included. Duplicate or insufficient reports were excluded. Figure [1](#F1){ref-type="fig"} shows the procedure of identifying and selecting studies.

Data extraction {#s4_3}
---------------

Two authors extracted the data from the eligible articles according to the inclusion criteria. Any disagreement was resolved during a discussion with a third author. The literature data were extracted individually. OR and its 95% confidence intervals (CI) were used to estimated the association between the GSTM1 or GSTT1 null polymorphism and bladder cancer susceptibility. We evaluated the quality of studies using the Newcastle--Ottawa Scale. (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) Scores 7 to 9 were defined as a high quality study, and a score \<7 as a low quality study.

Statistical analyses {#s4_4}
--------------------

A meta-analysis was performed to reveal the association between GSTM1/GSTT1 deletion polymorphisms and bladder cancer susceptibility. Subgroup analyses were performed on different ethnicity, population-based and smoking status. Statistical heterogeneity was assessed using a formal Q-statistic as well as I^2^ \[[@R80]\], P\<0.05 was considered statistically significant. A fixed-effect model was used when no heterogeneity was found; otherwise, the random-effect model was used to calculate pooled ORs. To validate the stability of results in this meta-analysis, a sensitivity analysis was carried out by sequential omitting each study and analyzing whether the significance of ORs was influenced excessively by omitting the study. Publication bias was evaluated by Egger\'s regression asymmetry test \[[@R81]\], and Begg\'s adjusted rank correlation test \[[@R82]\]; P\<0.05 was considered statistically significant. All analyses were performed using the STATA 11.0 statistical software (Stata Corp, College Station, TX, USA).
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